AstraZeneca expanded its global pharmacovigilance capabilities by partnering with external drug safety providers to manage growing volumes of adverse event reports and increasingly complex regulatory requirements. By outsourcing key pharmacovigilance functions, the company improved processing efficiency, strengthened compliance, and created a scalable safety monitoring framework capable of supporting its expanding global product portfolio.
Company
AstraZeneca
Services Provided
Adverse Event Case Processing
Safety Reporting
Signal Detection Support
Regulatory Documentation
Drug Safety Monitoring
Pharmacovigilance Operations Support
Industry
Pharmaceuticals and Life Sciences
Locations
Global Operations
Operating Model
AstraZeneca leveraged external pharmacovigilance providers to support operational drug safety activities while retaining responsibility for overall safety governance, regulatory strategy, and risk management.
Delivery Structure
Specialized pharmacovigilance teams managed adverse event processing, reporting, documentation, and safety monitoring activities across multiple markets, helping AstraZeneca maintain regulatory compliance and global safety oversight.
Why This Approach
As AstraZeneca expanded its portfolio of medicines and global market presence, pharmacovigilance operations became increasingly complex.
The company faced rising volumes of adverse event reports from healthcare professionals, patients, clinical studies, and post-market surveillance activities. At the same time, regulatory authorities worldwide introduced increasingly stringent drug safety and reporting requirements.
Maintaining continuous safety monitoring while scaling operations efficiently required additional resources and specialized expertise.
AstraZeneca needed a solution that could support growing pharmacovigilance demands without requiring continuous expansion of internal headcount.
Success Snapshot
Performance Drivers
- Dedicated pharmacovigilance support teams
- Standardized adverse event processing workflows
- Expanded global safety monitoring capabilities
- Specialized regulatory documentation support
- Scalable operational framework
- Continuous drug safety surveillance
Outcomes
- Faster adverse event processing
- Improved regulatory compliance
- Scalable global pharmacovigilance operations
- Enhanced regulatory readiness
- Reduced pressure on internal safety teams
Company Background
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines across multiple therapeutic areas.
Drug safety and patient protection are critical components of pharmaceutical operations. Regulatory authorities require manufacturers to continuously monitor product safety, assess risks, process adverse event reports, and maintain extensive documentation throughout a product’s lifecycle.
As product portfolios expand, pharmacovigilance operations become increasingly resource-intensive and operationally complex.
Industry and Operating Context
Pharmaceutical companies operate within one of the most heavily regulated industries in the world.
Drug safety programs require continuous monitoring of adverse events, timely reporting to health authorities, ongoing risk assessments, and extensive documentation management.
The volume of safety data can increase significantly as products expand into new markets, patient populations, and therapeutic applications.
To manage these demands, many pharmaceutical organizations partner with specialized pharmacovigilance providers that offer scalable resources, regulatory expertise, and dedicated safety operations support.
Core Problem
AstraZeneca’s challenge centered on scaling drug safety operations to meet growing global demands.
Increasing numbers of adverse event reports required additional processing capacity, while evolving international regulations created greater documentation and compliance requirements.
The company also needed to maintain continuous safety monitoring across multiple regions and products, creating pressure on internal pharmacovigilance teams.
Without a scalable support model, sustaining regulatory compliance and operational efficiency would become increasingly difficult as reporting volumes continued to grow.
Offshore Solution
AstraZeneca partnered with external pharmacovigilance providers to support critical drug safety functions.
The outsourced teams were responsible for:
- Adverse Event Case Processing
- Safety Reporting
- Signal Detection Support
- Regulatory Documentation
- Pharmacovigilance Operations Support
These specialized resources helped manage increasing safety workloads while supporting compliance with global regulatory requirements.
By shifting execution-heavy pharmacovigilance activities to dedicated providers, AstraZeneca was able to maintain comprehensive safety oversight while creating greater operational flexibility and scalability.
Results
The pharmacovigilance outsourcing strategy enabled AstraZeneca to strengthen its global drug safety infrastructure while improving operational efficiency.
Adverse event reports were processed more quickly, helping support timely safety assessments and regulatory submissions.
The expanded operational capacity also improved compliance readiness and allowed the company to respond more effectively to evolving regulatory expectations across different markets.
Most importantly, AstraZeneca achieved greater scalability in its pharmacovigilance operations without the need for continuous growth in internal staffing levels.
Measurable Outcomes
- Faster adverse event processing
- Improved compliance performance
- Enhanced regulatory readiness
- Scalable global safety operations
- Increased pharmacovigilance capacity
Operational Outcomes
- Improved case processing efficiency
- Stronger safety reporting capabilities
- Expanded global monitoring coverage
- Better documentation management
- Increased operational flexibility
Business Impact
- Reduced dependence on internal headcount growth
- Strengthened global drug safety infrastructure
- Improved support for expanding product portfolios
- Enhanced regulatory compliance capabilities
- Enabled sustainable long-term operational scaling
Conclusion
AstraZeneca’s pharmacovigilance outsourcing strategy demonstrates how pharmaceutical companies can address growing drug safety demands while maintaining regulatory excellence.
By partnering with specialized pharmacovigilance providers, the company accelerated adverse event processing, improved compliance readiness, and expanded its global safety monitoring capabilities. Rather than continuously increasing internal staffing levels, AstraZeneca created a scalable operational model capable of supporting both current requirements and future growth.
The result was a more flexible and efficient pharmacovigilance function that strengthened patient safety oversight while supporting the company’s global pharmaceutical operations.
